Seoul National University Bundang Hospital Establishes the first “International PSP Research and Treatment Center” in Korea
MOU Signed Among SNUBH-CurePSP-GemVax for the Establishment of International PSP Research and Treatment Center Tackling Global Challenges in an Aging Era… "Aspiring to become a global research and treatment hub for the rare neurodegenerative disease" SEOUL, South Korea, Dec. 9, 2024 /PRNewswire/ -- Seoul National University Bundang Hospital ("SNUBH"), CurePSP, Inc....
Actinogen randomizes first US participant in XanaMIA phase 2b/3 Alzheimer’s disease trial
Late-stage trial in Alzheimer's opens 10 sites in US, with results due in 2025 and 2026 Appoints US-based Chief Commercial Officer, Andrew Udell Xanamem's unique ability to control brain cortisol draws widespread coverage in the Australian media. SYDNEY, Dec. 9, 2024 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW)...
Concord Healthcare Announces Approval Granted to the Application for the Proton Therapy Equipment Registration Certificate
BEIJING, Dec. 9, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that the National Medical Products Administration of the People's Republic of China has granted approval to the application for the Registration Certificate for Medical Device for the...
Dizal Presents Latest Data of DZD8586, a LYN/BTK Dual Inhibitor, in B-cell Non-Hodgkin Lymphoma at the 2024 ASH Annual Meeting
DZD8586 demonstrated encouraging anti-tumor activity with manageable safety and favorable pharmacokinetic (PK) characteristics in patients with B-NHL SHANGHAI, Dec. 9, 2024 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced the latest data from a pooled safety and efficacy analysis...
Dr. James G. Fujimoto of U.S. Awarded 45th Honda Prize for His Team’s Development of Optical Coherence Tomography (OCT): Real-time Tissue Imaging Technology
- OCT Marks Breakthrough in Disease Detection and Manufacturing - TOKYO, Dec. 9, 2024 /PRNewswire/ -- The Honda Foundation in Tokyo held the 45th Honda Prize Award Ceremony on November 18, 2024, where this year's prize was awarded to Dr. James G. Fujimoto, Elihu Thomson Professor of Electrical Engineering and Computer Science, Research Laboratory of Electronics, Massachusetts Institute of...
BRIDGING CLINICAL RESEARCH AND CLINICAL CARE WITH AI-AIDING PATHOLOGISTS TOOL
SINGAPORE, Dec. 9, 2024 /PRNewswire/ -- A newly published collaborative study in the Journal of Hepatology, featuring HistoIndex – a global leader in stain-free digital pathology solutions for managing fibrotic diseases – alongside Merck & Co., MSD, Virginia Commonwealth University (VCU), The National Institutes of Health (NIH) and a panel of distinguished international liver pathologists showcased how Artificial Intelligence (AI)...
Reimagining our urban futures: Health-Driven Design for Cities (HD4) research programme launches in Singapore
SINGAPORE, Dec. 9, 2024 /PRNewswire/ -- December sees the launch of Health-Driven Design for Cities (HD4), a groundbreaking Singapore-based research collaboration seeking to discover how best to design urban environments that enhance the health of their residents. HD4 is a partnership between Nanyang Technological University, Singapore (NTU Singapore) the National University of Singapore (NUS), and the University of Cambridge. It...
2024 ASH Oral Presentation—-Abbisko presents promising preliminary phase 2 study results of pimicotinib in the treatment of Chronic Graft-versus-Host Disease (cGvHD) at the 66th ASH Annual Meeting
SHANGHAI, Dec. 9, 2024 /PRNewswire/ -- December 8, 2024, Abbisko Therapeutics (HKEX: 02256) announced the presentation of preliminary Phase 2 study results for pimicotinib (ABSK021) in patients with chronic Graft-versus-Host Disease (cGvHD) who have either progressed or not responded to one or more prior lines of therapy. The presentation took place at the 66th ASH Annual Conference, held December...
Jacobio Pharma Presented preliminary Data on BET Inhibitor for Myelofibrosis at 2024 ASH
BEIJING, SHANGHAI and BOSTON, Dec. 9, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company dedicated to developing therapies toward undruggable targets, today presented preliminary Phase I data of BET inhibitor JAB-8263 to treat myelofibrosis (MF) at the 2024 ASH (American Society of Hematology) Annual Meeting in San Diego, California. The data showed that JAB-8263 was well tolerated...
Encouraging Efficacy and Safety: CStone Presents Latest Clinical Data on CS5001 for Advanced Lymphoma at the 66th ASH Annual Meeting
CS5001 is so far the first anti-ROR1 ADC known to show clinical anti-tumor activity in both solid tumors and lymphomas. The data presented at ASH highlighted the latest safety and efficacy of CS5001 as a monotherapy for patients with advanced lymphomas. CS5001 is well tolerated in heavily pre-treated patients with advanced B-cell lymphoma. No dose-limiting toxicity (DLT) has been reported up...
